Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells

被引:20
作者
Akinmade, D. [1 ,2 ]
Talukder, A. H.
Zhang, Y. [1 ,2 ]
Luo, W-m [1 ]
Kumar, R. [3 ]
Hamburger, A. W. [1 ]
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21210 USA
[2] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Ebp1; PA2G4; phosphorylation; PAK1; breast cancer;
D O I
10.1038/sj.bjc.6604261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ErbB3 binding protein ( Ebp1) is a transcriptional corepressor that inhibits the activity of proliferation- associated genes and the growth of human breast cancer cell lines. Treatment of breast cancer cells with the ErbB3 ligand heregulin ( HRG) results in increased phosphorylation of Ebp1 and transcriptional repression. The p21- activated serine/ threonine kinase 1 ( PAK1), which plays an important role in breast cancer progression and resistance to the anti- oestrogen tamoxifen, is also activated by HRG. We therefore examined the ability of PAK1 to phosphorylate and regulate the function of Ebp1. We found that PAK1 phosphorylated Ebp1 in vitro and mapped the phosphorylation site to threonine 261. Both HRG treatment and expression of a constitutively activated PAK1 in MCF- 7 breast cancer cells enhanced threonine phosphorylation of Ebp1. In MCF- 7 cells, ectopically expressed Ebp1 bound endogenous PAK1 and this association was enhanced by treatment with HRG. Mutation of the PAK1 phosphorylation site to glutamic acid, mimicking a phosphorylated state, completely abrogated the ability of Ebp1 to repress transcription, inhibit growth of breast cancer cell lines and contribute to tamoxifen sensitivity. These studies demonstrate for the first time that Ebp1 is a substrate of PAK1 and the importance of the PAK1 phosphorylation site for the functional activity of Ebp1 in breast cancer cells.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 39 条
[1]   Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase [J].
Adam, L ;
Vadlamudi, R ;
Kondapaka, SB ;
Chernoff, J ;
Mendelsohn, J ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :28238-28246
[2]   Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase [J].
Ahn, Jee-Yin ;
Liu, Xia ;
Liu, Zhixue ;
Pereira, Lorena ;
Cheng, Dongmei ;
Peng, Junmin ;
Wade, Paul A. ;
Hamburger, Anne W. ;
Ye, Keqiang .
EMBO JOURNAL, 2006, 25 (10) :2083-2095
[3]  
Akinmade D, 2007, INT J ONCOL, V31, P851
[4]   p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells [J].
Balasenthil, S ;
Sahin, AA ;
Barnes, CJ ;
Wang, RA ;
Pestell, RG ;
Vadlamudi, RK ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (02) :1422-1428
[5]   Functional inactivation of a transcriptional corepressor by a signaling kinase [J].
Barnes, CJ ;
Vadlamudi, RK ;
Mishra, SK ;
Jacobson, RH ;
Li, F ;
Kumar, R .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (08) :622-628
[6]   An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels [J].
Diamonti, AJ ;
Guy, PM ;
Ivanof, C ;
Wong, K ;
Sweeney, C ;
Carraway, KL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2866-2871
[7]   The ErbB receptors and their role in cancer progression [J].
Holbro, T ;
Civenni, G ;
Hynes, NE .
EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :99-110
[8]   The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation [J].
Holbro, T ;
Beerli, RR ;
Maurer, F ;
Koziczak, M ;
Barbas, CF ;
Hynes, NE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8933-8938
[9]   Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients [J].
Holm, Caroline ;
Rayala, Suresh ;
Jirstrom, Karin ;
Stal, Olle ;
Kumar, Rakesh ;
Landberg, Goeran .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) :671-680
[10]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354